The COVID-19 section features the latest safety alerts related to drugs being investigated as potential treatments, vaccinations or supportive care.
To complement the efforts being made worldwide in the fight against COVID-19, Bioinfogate is pleased to announce that they are providing complimentary access to a dedicated “COVID-19” section in OFF-X, the translational safety information portal. This section features the latest safety alerts related to drugs being investigated as potential treatments, vaccinations or supportive care.
Updated as soon as new information becomes available, the COVID-19 section provides a compilation of safety alerts derived from recent publications related to COVID-19 as well as previous OFF-X content that may be of interest.
Dr Josep Prous, Jr, Executive Director at Bioinfogate commented: “We are very pleased to be able to contribute to the global efforts being made to tackle this pandemic, by helping optimize pharmaceutical R&D and minimize patient risks in clinical trials and beyond”.
The COVID-19 report can be accessed via the OFF-X home page, from the Selected Daily Alerts section. Content can be sorted and/or filtered by target, drug of interest or date. Clicking on any alert jumps to OFF-X and the full alert details.
Bioinfogate is a forward thinking, private company working to solve unmet medical needs. Our innovative data science products support the discovery and development of better and safer drugs. We are committed to building industry-leading solutions and identifying / investing in emerging projects that align with our core business in the life sciences and data analytics.
Our passion and capabilities stem from more than 60 years of experience creating and managing biomedical knowledge, first at Prous Science (1958-2007), acquired by Thomson Reuters in 2007 (now Clarivate Analytics), and then at Prous Institute for Biomedical Research. Bioinfogate is the latest initiative within the Prous family group of companies embracing a long tradition and expertise in scientific knowledge management.